Symbiotec Pharmalab IPO has entered its final bidding day with the issue subscribed 5.31 times and the grey market premium indicating a potential 29% listing gain over the upper price band.
NEW DELHI, India — Symbiotec Pharmalab IPO opened for its fourth and final day of bidding on August 27, 2026, with investors tracking subscription demand and grey market trends. The Rs 1,757 crore issue had received 5.31 times overall subscription, while its grey market premium (GMP) stood at around Rs 285 per share.
Key Highlights
- Symbiotec Pharmalab IPO was subscribed 5.31 times overall by Day 4.
- The GMP of Rs 285 indicates a potential 29% premium over the Rs 988 upper price band.
- Retail investors subscribed 5.05 times, while the NII portion reached 12.18 times.
- The IPO closes on August 27, with allotment expected on August 28.
- The shares are tentatively scheduled to list on the BSE and NSE on September 1.
Symbiotec Pharmalab IPO Subscription Status
The public issue has attracted significant demand during its subscription window. Against 1.31 crore shares available for subscription, the IPO had received 5.31 times overall bidding.
Retail Individual Investors subscribed 5.05 times against 65.44 lakh shares reserved for them. The Non-Institutional Investor category recorded 12.18 times subscription against 28.04 lakh shares on offer.
Qualified Institutional Buyers subscribed to 59% of their reserved portion, which consists of 37.39 lakh shares.
Symbiotec Pharmalab IPO GMP Today
The Symbiotec Pharmalab IPO GMP is currently around Rs 285 per share. When added to the upper issue price of Rs 988, the unofficial indication points towards an estimated listing price of approximately Rs 1,273.
This translates into a potential listing premium of nearly 29% over the upper price band. However, grey market premium is an unofficial indicator and can change before the actual stock market debut.
Investors should therefore consider the company’s fundamentals, valuation and associated risks rather than relying only on GMP while evaluating the IPO.
Symbiotec Pharmalab IPO Price Band and Investment
The company has fixed the IPO price band at Rs 938 to Rs 988 per share. Investors can bid for a minimum of 15 shares and in multiples of 15 thereafter.
At the upper price band, the minimum investment for one retail lot is Rs 14,820. The IPO opened on August 24 and is scheduled to close on August 27, 2026.
IPO Size and Use of Proceeds
Symbiotec Pharmalab is raising Rs 1,757 crore through the public issue. The offering includes a fresh issue of 15 lakh shares worth Rs 150 crore and an offer for sale of 1.63 crore shares amounting to Rs 1,607 crore.
From the IPO proceeds, Rs 112.50 crore is proposed to be used for the prepayment or repayment, either fully or partially, of selected outstanding borrowings. The remaining funds are planned for general corporate purposes.
Symbiotec Pharmalab IPO Valuation
Based on diluted fiscal 2026 earnings per share, the IPO’s price-to-earnings ratio stands at 49.37 times at the lower end of the price band and 52 times at the upper end.
The company’s weighted average return on net worth for the previous three financial years was 10.99%. The price band represents 469 times the face value at the floor price and 494 times at the cap price.
About Symbiotec Pharmalab
Founded in 2002, Symbiotec Pharmalab operates in biopharmaceutical and biotechnology manufacturing. The company develops and manufactures active pharmaceutical ingredients, nutritional ingredients and specialised products for domestic and international markets.
Its operations include capabilities in steroidal and corticosteroid APIs, CDMO services and complex pharmaceutical manufacturing. The company has also received approvals and certifications from international regulatory bodies, including the US FDA, EU-GMP authorities and South Korea’s Ministry of Food and Drug Safety.
As of June 30, 2025, Symbiotec Pharmalab operated two industrial-scale API manufacturing plants. Together, the facilities had maximum capacity of 584.67 metric tonnes for chemical synthesis and 300 kilolitres of fermentation capacity.
Should You Subscribe to Symbiotec Pharmalab IPO?
The IPO combines exposure to specialised pharmaceutical manufacturing with the company’s capabilities in APIs, biotechnology and regulated manufacturing. Its backward-integrated operations and international regulatory approvals are among the factors highlighted in the supplied brokerage research.
Master Capital Services said the global API market was valued at around USD 305.5 billion in 2025 and is expected to reach USD 424.6 billion by 2030, with a projected 6.8% CAGR. The report also highlighted growth potential in CDMO services and India’s manufacturing capabilities.
According to the report, Symbiotec Pharmalab could provide a long-term investment opportunity through its specialised manufacturing capabilities and exposure to pharmaceutical markets. Investors should independently assess the offer documents, valuation and risks before making any decision.
Symbiotec Pharmalab IPO Allotment and Listing Date
The IPO closes on August 27, 2026, after which allotment is expected to be finalised on August 28. The shares are tentatively scheduled to list on both the BSE and NSE on September 1.
The current GMP suggests a potential 29% listing premium, but the actual listing price will be determined by market conditions when trading begins.
Financial disclaimer: This article is for informational purposes only and should not be treated as investment advice. IPO investments are subject to market risks.
Praveen Yadav is the Founder and Editor at The Nation Bulletin. With over 3 years of experience in digital journalism and news reporting, he covers national affairs, governance, and breaking current events with a commitment to factual accuracy and verified reporting.
